Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 2
Submit an article Journal homepage
268
Views
2
CrossRef citations to date
0
Altmetric
Articles

Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia

Jan Philipp Bewersdorfa Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAORCID Iconhttps://orcid.org/0000-0003-3352-0902View further author information
ORCID Icon,
Kishan K. Patelb Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USAView further author information
,
George Goshuac Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA;d Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USAView further author information
,
Rory M. Shallisc Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA;e Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USAORCID Iconhttps://orcid.org/0000-0002-8542-2944View further author information
ORCID Icon,
Nikolai A. Podoltsevc Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA;e Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USAView further author information
,
Maximilian Stahlf Department of Medical Oncology, Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
,
Eytan M. Steina Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Scott F. Huntingtonc Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA;e Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USAView further author information
&
Amer M. Zeidanc Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA;e Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USACorrespondence[email protected]
View further author information
 show all
Pages 454-461 | Received 09 Sep 2022, Accepted 16 Oct 2022, Published online: 09 Dec 2022

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.